





Sustainability 2021, 13, 9792. https://doi.org/10.3390/su13179792 www.mdpi.com/journal/sustainability 
Article 
Determinants of Internationalization as Levers  
for Sustainability: A Study of the Portuguese  
Pharmaceutical Sector 
Jorge Vieira *, Rui Frade, Raquel Ascenso, Filipa Martinho and Domingos Martinho 
ISLA Santarém, Largo Cândido Reis, 2000-241 Santarém, Portugal; rui.frade@islasantarem.pt (R.F.); 
raquel.ascenso@islasantarem.pt (R.A.); filipa.martinho@islasantarem.pt (F.M.);  
domingos.martinho@islasantarem.pt (D.M.) 
* Correspondence: vieira.jm@gmail.com 
Abstract: The pharmaceutical industry is facing the pressure of a global economy, loss of value in 
local markets and the highly intense innovation that characterizes this sector. This has a heavy 
impact, particularly in smaller economies. With this investigation, we intend to identify the 
determinants of internationalization as levers for sustainability in the pharmaceutical export sector 
of a small economy. Data was collected from a sample representing 63% of the total universe, 
Portuguese pharmaceutical organizations with exporting activity. A contextualization of the sector 
and a bibliographic review were previously carried out, which laid the groundwork for the 
empirical framework. This study revealed a deeply internationalized sector conditioned by a few 
shortcomings, namely a certain lack of sustainable competitive advantages, relatively low 
investment in research and development (R&D), insufficient innovation in internationalization 
strategies as well as scarce institutional support. Our findings may help pave the way for a more 
complete understanding of the dynamics of internationalization in highly competitive sectors. 
Keywords: pharmaceutical industry; internationalization determinants; internationalization 
strategy; levers for sustainability 
 
1. Introduction 
“Big Pharma” dominates the global landscape. The major pharmaceutical firms are 
international players with considerable power in their home countries and substantial 
presence in much of the world’s markets. Local companies need to survive in this 
environment [1,2]. This research consists of a study of local pharmaceutical companies to 
examine key variables, extracted from academic literature, that are associated with or 
contribute to the success of internationalization projects and, potentially, the 
organization’s sustainability. Companies that, until recently, benefited from comfortable 
positions in local markets, can see those positions threatened by global competition [2]. 
This is the context in which we frame the Portuguese pharmaceutical industry (PPI), 
whose sustainability is currently considered at risk due to the sector’s aggressive 
competitiveness for innovation and the demand for resources [1]. In this specific sector, 
sustainability strongly relies on international operations and, consequentially, 
internationalization emerges as a lever for economic and business sustainability. 
In order to understand this phenomenon, we carried out a literature review to frame 
internationalization strategies within the scope of the pharmaceutical industry (PI). This 
review led us to isolate the research problem and to formulate the following research 
question: What are the determining factors for sustainability in the internationalization of 
the PPI? 
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The exporting PPI faces the imperative of expanding to foreign markets as a source 
of self-sustainability. This study intends to be a small contribution to the body of 
knowledge of the internationalization processes, framed in an economy with few 
resources when compared to international players. At an operational level, we expect to 
identify strategic orientations and key factors for successful projects and better overall 
results from internationalization ventures. 
2. Background 
2.1. Pharmaceutical Industry 
PI plays an undeniable role as a strategic sector to every country by contributing 
towards improving the population’s quality of life [1,2]. This fact is expressed objectively 
by many indicators, from a higher life expectancy to the overall better quality of life of 
patients affected by numerous pathologies (oncology, AIDS, cardiovascular, the current 
pandemic situation, among others) or even by the impact that some drugs have on global 
economic indicators [1]. 
In the last twenty-five years, the majority of blockbuster medicines that supported 
the sustainability of Big Pharma, saw a drastic decrease in sales volume as a direct 
consequence of expiring patents. This was complemented by a burst in generic medicines 
sales across the global market, setting the stage for the development of companies with 
local or regional dimension that rapidly adapted their activities to the manufacture and 
commercialization of this type of products. However, less technologically complex 
activities (manufacturing of raw materials, intermediate products, and drugs with small 
or no differentiation) are associated with lower financial margins [3–5]. For this reason, 
the PI tends to develop new and innovative drugs, associated with much better margins, 
particularly during the period of exclusivity associated with innovation patents [5–7]. 
Nevertheless, the development of a new drug is a risky and resource-intensive endeavor. 
It frequently involves a strong financial investment, often over one billion euros [8], and 
long development times for a new medicine to be marketed. In the last twenty-five years, 
research and development (R&D) costs have tripled in Europe [1,5]. 
Big Pharma tried to leverage the sustainability of these large investments by 
intensifying international efforts, with the goal of achieving swift returns on their 
investment, in a shorter period of time. Brand new medicines are usually associated with 
considerably higher sales prices, especially the most technologically sophisticated (for 
example, the new monoclonal antibodies for oncological pathologies) [1,8]. As such, despite 
the global increase in sales associated with generic medicines, characterized by having 
sales prices far below their brand equivalents, the international pharmaceutical market 
continues to grow remarkably (see Table 1). 
Globally, the pharmaceutical market generates approximately 1060 billion euros. 
North America (United States and Canada) accounts for about 45% of the market, Europe 
23%, China 10%, Japan 7%, and the remaining countries only 11%. The Portuguese market 
is considered objectively small in the global context [9]. 
Table 1. World Pharmaceutical Market. 
 2018 2019 2020 
 Sales M.S.% Sales M.S.% Sales M.S.% 
North America 433,262 44.7% 457,197 44.4% 478,676 45.3% 
Europe 215,882 22.3% 229,876 22.3% 240,379 22.7% 
China 105,859 10.9% 115,607 11.2% 103,408 9.8% 
Japan 72,429 7.5% 73,973 7.2% 72,732 6.9% 
Latin America 36,140 3.7% 39,130 3.8% 44,001 4.2% 
Portugal 3670 0.4% 3860 0.4% 3945 0.4% 
Rest of World 102,262 10.5% 110,555 10.7% 114,582 10.8% 
World 969,504 100% 1,030,199 100% 1,057,723 100% 
Sales: yearly annual turnover (million euros); M.S.%: market share. Source [9]. 
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2.2. The Internationalization of Pharmaceutical Companies 
Internationalization has been the subject of intense investigation in the last decades, 
with the definition of several theories that explain this phenomenon from different 
perspectives. However, few are the papers specifically focused on studying PI’s 
internationalization [7,10–23] (see Appendix A). When analyzing these studies we 
observed highly dispersed criteria, methodologies, and objectives. This limitation was 
also mentioned by other authors in previous research [7]. None of these studies investigate 
internationalization as a source of sustainability. The most frequently referred theoretical 
frameworks are the internationalization models based on resources [24], the incremental 
internationalization [25], and the eclectic paradigm [26]. These choices reflect researchers’ 
concerns when evaluating the use of companies’ internal resources and their ability to 
create the necessary conditions for international expansion while, simultaneously, 
identifying incremental internationalization trends, from sporadic exports to establishing 
manufacturing facilities abroad [27]. A set of attributes or determinants in the 
internationalization process were identified as well: international strategic orientation 
(ISO), entry mode selection (EM), competitive advantages (CA), internationalization 
barriers (IB), and the role of R&D [7,8,11,12,14,15,19,22]. 
2.3. The Portuguese Pharmaceutical Industry 
In a global context, the Portuguese pharmaceutical industry is relatively small, 
consisting mainly of small and medium-sized companies [28]. The domestic market is 
valued at approximately 3.95 billion euros, which represents only 0.4% of the global 
market [9]. Investment in innovation follows a slight upwards trend, virtually 
insignificant when compared to similar economies like Austria, Cyprus or Slovenia [1,29]. 
This paradigm reveals a situation of relative weakness, especially for companies for which 
the local market is the main source of income. 
The history of the PPI’s internationalization is relatively recent. In 2017, export 
figures were roughly one billion euros, about 2% of country’s total exports [28,30]. Despite 
the recent surge in exports, the Portuguese pharmaceutical products’ trade balance is 
strongly negative, −1489 million euros in 2017 [31], a fact that conditions the sustainability 
of the pharmaceutical sector. 
PPI’s export intensity (percentage of products sold abroad) has more than doubled 
since 2010. Similarly, the level of imports covered by exported goods or services in the 
pharmaceutical sector has increased twofold in recent years. This phenomenon was 
significantly more evident than in other industrial sectors. However, the penetration rate 
of imports in the domestic market (percentage of supply in the Portuguese market 
imported from abroad) is significantly larger than the national average and has increased 
in recent years, exposing the sector’s strong dependence on foreign entities (see Table 2) 
[30]. These seemingly contradictory indicators are at the heart of this study’s academic 
relevance and ambition. 
Table 2. Export Economic Indicators for Portuguese Pharmaceutical Industry. 
Mean Yearly Value% 2008–2010 2011–2013 2014–2016 
Export Intensity (1) 
PT 14.0 17.9 19.5 
PPI 42.8 62.5 85.7 
Coverage rate of imports by 
exports (2) 
PT 70.9 87.8 90.3 
PPI 22.9 31.6 40.6 
Import penetration rate on the 
domestic market (3) 
PT 18.7 19.9 21.1 
PPI 76.5 84.1 93.7 
(1) How much of the local production is exported. (2) What percentage of imports is offset by 
exports. (3) How much of the local supply is imported. PT: Country’s average; PPI: only 
Portuguese pharmaceutical industry. 
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3. Theoretical Framework 
The understanding of internationalization phenomena has undergone an enormous 
evolution since the 1960s, from the classic models based on economic power to models 
based on relations of multipolar cooperation. First theories were influenced by the post-
World War II environment and the strong internationalization movement of the American 
production industry [32]. These refer to the importance of acquiring resources for 
manufacturing goods or provide services to create profit. Company resources are the 
bedrock for developing sustainable competitive advantages [24,33–35]. In the later 1970s, 
new behavioral approaches emerged. The most cited in academic literature are the 
Uppsala incremental model [25] and the Eclectic paradigm [26]. Recently, new 
perspectives emerged, highlighting the significance of professional networking in 
internationalization decisions [36]. According to these new models, resource allocation is 
mediated through interactions between companies [37]. Despite the high volume of 
theories and experimental models, there is still no model that holistically explains 
internationalization and, above all, with practical applicability to support companies’ 
strategic decision making [27,35]. 
3.1. Determinants of Pharmaceutical Industry Internationalization 
The main goal of this study is not to identify the determining factors for 
internationalization performance. This has already been the subject of previous research, 
by other authors, which has greatly contributed to the body of knowledge in this field 
[38]. The characterization and relevance of such factors, however, are still somewhat 
limited, i.e., researchers find a lack of information when trying to identify the relevant 
determinants of internationalization in a specific economic sector. To overcome this 
limitation, our study follows a different path, studying the internationalization 
determinants previously identified in the literature that can be particularly relevant to the 
pharmaceutical sector. This enabled the identification of a set of variables, determinants 
of the sustainability in the pharma environment [7,11–23], further elaborated in the 
following points. 
3.1.1. Internationalization Strategic Orientation 
Managers’ internationalization strategic orientation (ISO) is essential to 
understanding the need to expand operational activity to foreign markets, adequate 
allocation of resources, international strategy development, and, particularly, how 
opportunities in foreign markets are perceived and identified [39]. Reluctance in the 
adoption of internationalization strategies can be a consequence of insufficient 
determination by top managers [40] which, in turn, can be a limitation to the overall 
success of internationalization ventures. This means that one of the fundamental aspects 
in the definition of a company’s foreign strategy is the attitude of the top managers since, 
too often, foreign expansion results in nothing more than the application of the local 
business plan to external markets [41,42]. 
Shoham [43] argued that the choice between different ISO’s, by itself, would not 
impact international performance. He demonstrated that the subjective perception of 
internationalization factors did not suffer any variations from the different strategic 
orientations. However, the PPI is still heavily reliant on the domestic market and, as such, 
we propose the following hypotheses as a method for understanding the importance of 
the ISO in international performance: 
Hypothesis 1a (H1a). Different ISOs have different levels of turnover. 
Hypothesis 1b (H1b). Different ISOs have different levels of international business turnover. 
  
Sustainability 2021, 13, 9792 5 of 17 
 
3.1.2. Competitive Advantages 
A company’s profitability is directly proportional to its ability to build and exploit 
advantages in the markets where it operates [24,44,45]. Competitive advantages (CA) arise 
fundamentally from the value that a company can create for customers, exceeding the cost 
associated with it. Sustained competitive advantages result from the creation of added-
value strategies, as distinct and inimitable as possible, for competing companies [3,24]. 
The different sources of competitive advantages, costs (CCA), service (SCA), or product 
(PCA), reflect the company’s ability to allocate its resources better than competing 
companies, in the creation of perceived value for its customers [46,47]. 
Kaleka and Morgan [48] studied the interactions between CA and performance in 
foreign markets, revealing the existence of positive correlations between CA and stronger 
international results. Ferreira and Simões [46] noted that the CCA have a positive impact 
on economic performance while the SCA and PCA only appear to positively affect the 
subjective parameters of internationalization performance. In this research we 
hypothesize the following: 
Hypothesis 2a (H2a). Companies with more CA are associated with a larger turnover. 
Hypothesis 2b (H2b). Companies with more CA are associated with larger international business 
turnover. 
Hypothesis 2c (H2c). Companies with more CA are associated with ISOs focused on foreign 
markets. 
3.1.3. Barriers in the Process of Internationalization 
The internationalization process can often become problematic, as companies are 
faced with obstacles while implementing planned strategies [49]. The complexity in 
registering new drugs, limited access to licenses or reimbursements from governmental 
entities and the existence of patents are good examples of barriers to the 
internationalization of pharmaceutical companies [7]. These barriers (IB) can have 
different effects: discourage internationalization by non-exporting companies, inhibit 
exporting attitudes, can induce disinvestment decisions or be the dissuading factor for an 
ex-exporting company to resume its internationalization projects [49]. Managers’ 
international experience and professional networking can be important to minimize the 
perception of barriers to internationalization [7,12,49,50]. From a conceptual standpoint, 
we can divide these barriers into internal (IIB), inherent to the company, in regard to the 
strategic definition and allocation of resources, and external (EIB), related to the market 
environment and external context [49]. 
Anil et al. [51] evaluated the impact of IB’s in internationalization performance. 
Contrary to what was expected, this research revealed a positive impact of EIB on 
international activities, a surprising result in the author’s opinion. Safari and Saleh [52] 
found only one indirect negative result of IB in international results, through a mediating 
effect in the business strategy. Thus, we hypothesize that: 
Hypothesis 3a (H3a). Companies with more IB are expected to have less international business 
turnover. 
Hypothesis 3b (H3b). Companies with more IB are expected to have less CA. 
Hypothesis 3c (H3c). Companies with less IB are expected to have ISOs focused on foreign 
markets. 
3.1.4. Entry Mode Selection 
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The choice of entry mode (EM) is one of the most important strategic decisions in an 
internationalization process [4]. It can have a direct impact on the project’s performance 
since poor decisions can have lasting effects in the entire strategy and future options. EM 
can be grouped according to the need for required investment: no investment (WEM): 
exports, licensing contracts, franchising; or with investment (IEM): joint ventures, 
acquisitions, and establishment of subsidiaries [50]. The choice of EM is influenced, 
among other aspects, by the level of investment, risk exposure and the level of control that 
the company intends to have [4,53]. 
It is not yet clear if EM is, in fact, a determinant in the process of a company’s 
internationalization. In a recent review, Chan et al. [38] observed that this factor was given 
relatively low importance in academic research. It seems to serve more as a predictor of 
potential risks, operational control, and financial return, when conciliated with other 
determinants, namely IB [4,7,53]. Ulrich et al. [53] showed that IEM can have a positive 
impact in financial results as a consequence of higher investment levels and control over 
internationalization strategies and their implementation. While studying the 
internationalization process for pharmaceutical companies and the choice of EM, Wrona 
and Trąpczyński [7] noted that this decision results from weighting several aspects such 
as the market’s potential or level of product differentiation to be marketed as well as 
managers’ personal characteristics like international experience and risk perception. This 
led us to hypothesize: 
Hypothesis 4 (H4). IEM corresponds to ISOs focused on foreign markets. 
3.1.5. The Role of R&D 
Previous research established R&D activities in PI as a key determinant for 
sustainability in this particular sector [1,5,6–8]. While studying the Indian PI, Chitoor and 
Sougata [14] concluded about the importance of reinforcing investment and capacities in 
R&D to improve companies’ global competitiveness. They observed a strong correlation 
between companies with higher R&D investment levels, higher financial results, and 
degree of internationalization. A strong bet in R&D is the reflection of a strategic 
predisposition for innovation and new product development. Rentala et al. [22] noticed 
an association between reduced R&D levels and international performance. In a 2020 
paper, Teramae et al. [54] framed the current PI’s R&D model around sustainability. After 
analyzing thirty internationalized PI companies, they found a surprising negative 
correlation between R&D investment and revenue levels, despite the increase in total 
number of approved products. It is, therefore, crucial to understand if R&D investment is 
associated with better financial returns for PPI. Thus, we expect that: 
Hypothesis 5 (H5). Larger R&D investment is associated with larger international business 
turnover. 
3.1.6. Internationalization Performance 
Internationalization performance has been the object of intense research in the last 
decades. Chen et al. [38], in a recent bibliographical review, highlighted over one hundred 
key factors with direct impact on it. This study aims to identify determinants specific to 
sustainability within the PPI scope, as previously stated. As such, we adopted a 
parsimonious perspective, selecting two economic indicators to evaluate 
internationalization performance: total revenue and internationalization intensity 
(revenue percentage directly attributed to international business) [22,48]. We formulate 
hypothesis H1a, H1b, H2a, H2b, H3a, and H5, as previously presented, with the goal of 
identifying the determinants with relevant correlations with internationalization 
performance of the PPI. 
3.1.7. Research Framework 
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The proposed framework can be seen in Figure 1. A set of variables was additionally 
included in our research, aiming to provide a better contextualization of the PPI sector, 
namely the years of international activity, the volume of countries where the company is 
present, the total number of employees, the percentage of employees allocated to 
international activity and the main international activity (see Appendix B). 
 
Figure 1. Research Framework. CA—Competitive Advantages. EM—Entry Mode. IB—
Internationalization Barriers. ISO—International Strategic Orientation. IT—International Turnover. 
R&D—Research and Development. 
4. Methodology 
4.1. Methodological Options 
This study is quantitative in its nature [55,56]. The research datum was collected 
through a structured questionnaire (see Appendix B and C). The main goal of this research 
is to study the sustainability determinants of the PPI, forced to compete in a global 
environment dominated by the so called “Big Pharma”. For this reason, only the PPI 
manufacturers and exporters of pharmaceutical products (raw materials or drugs in their 
finished form) were selected. The selection was carried out by resorting to data from the 
Iberinform database [57]. We have selected all companies with the Portuguese activity 
classification (CAE) 21100 (basic pharmaceutical products manufacturer) and 21201 
(medicine manufacturer). Data selection took place on the 18 September 2019. Eighty-two 
companies were selected according to these criterions. Sample validation was carried out 
using available information on each company’s website and an additional contact via 
phone or email, when required, as to identify companies with current industrial and 
international activity. Sixty-six companies were excluded, thirty-four due to being 
subsidiaries and thirty-two because their current activity did not fall within the scope of 
our research. Thus, the final universe is comprised of sixteen companies that meet the 
eligibility criteria for this study: pharmaceutical company, producer, and exporter of 
pharmaceutical products, having Portugal as the center of international strategy’s 
decisions. 
Questionnaire datum was subjected to several tests, depending on the nature of the 
variables and the hypotheses being tested. We conducted a descriptive analysis on all 
variables; Spearman’s’ correlation tests were used to identify possible associations 
between ordinal variables; Mann–Whitney’s non-parametric tests were performed to 
identify differences between nominal and ordinal variables. A reliability test was also 
applied to the questionnaire, using Cronbach’s alpha calculation. In all tests, a significance 
level of p = 0.05 or lower was used, when applicable [55,56,58]. All data analysis was 
carried out using IBM© SPSS© 25 and Microsoft© Excel 2016. 
4.2. Questionnaire and Scales 
In order to collect the required quantitative data, a questionnaire was developed 
using scales previously validated in the scientific literature [43,48,59–62] as detailed in 
Appendix B. It underwent a reliability test to confirm its internal consistency, using the 
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Cronbach’s alpha calculation [56,63,64]. The complete questionnaire has a reasonable α = 
0.691. This survey was conducted using the Google Forms platform [65]. 
4.3. Sampling Process 
The target population is comprised of 16 companies. Due to the relatively small size 
of the universe in scope we opted for studying it in its entirety, as recommended [66,67]. 
Despite several attempts, we obtained a total of 10 responses, representing 63% of the 
universe, a significant value. We consider that this response rate was impacted by 
limitations derived from the pandemic situation in Portugal during the period when this 
study was being carried out. Since datum was not collected for the universe in full, we 
submitted our sample to an additional representativeness test [63]. We selected three 
variables and nine stratification items, based on data referenced in the literature on PI. 
High levels of representativeness were observed in all nine items, regardless of the 
stratification variable used. It is important to remember that the object of this investigation 
is a specific industrial sector of a country. All studies related to the internationalization of 
pharmaceutical companies are characterized by having relatively small samples (see 
Appendix A). According to Quivy and Campenhoudt [56] and the recommended 
prudence by Kruskal and Mosteller [67] regarding the use of the word 
“representativeness”, considering that our sample is highly homogeneous, it is reasonable 
to conclude that it is representative of the studied sector. A pre-test was carried out, with 
two in-person questionnaires. This procedure confirmed that each question was correctly 
understood, allowing us to capture the desired perception of the original scales. Top 
managers from each company (members of the Board of Directors, General Managers, and 
International Senior Managers) were contacted between the 1 December 2019and the 31 
March 2020, and invited to participate in this research. 
5. Findings 
5.1. Descriptive Analysis 
Table 3 represents a summary of the descriptive analysis for all variables and 
dimensions. 




Mean Median SD 
International Strategical Orientation (ISO) 1 1.80 2.00 0.42 
Entry Mode (EM) 1 1.20 1.00 0.42 
Competitive Advantages (CA) 10 4.40 4.00 0.84 
Cost Competitive Advantages (CCA) 2 4.20 4.00 0.92 
Service Competitive Advantages (SCA) 5 4.50 4.50 0.85 
Product Competitive Advantages (PCA) 3 3.90 4.00 0.74 
Internationalization Barriers (IB) 12 4.40 4.50 0.97 
Internal Internationalization Barriers (IIB) 6 4.10 4.00 1.10 
External Internationalization Barriers (EIB) 6 4.80 5.00 0.79 
Years of International Activity 1 5.00 4.50 1.25 
Countries with International Activity 1 6.20 7.00 1.40 
Yearly Turnover 1 5.00 5.00 2.00 
% Turnover from international business 1 4.60 4.50 1.90 
% Turnover to R&D 1 4.20 4.00 2.39 
Total number of Employees 1 6.20 7.00 1.03 
% Employees to international business 1 2.20 1.50 1.93 
Main International Activity 1 1.80 2.00 0.42 
See Appendix B for item scale response sets. 
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The descriptive analysis reveals that the PPI is comprised of companies significantly 
larger than the country’s average business, in terms of global revenue and number of 
employees. The PPI shows relatively high international experience levels, both in activity 
duration and number of markets with reported activity. Nonetheless, the sector reveals a 
low degree of innovation within the remit of internationalization and reduced 
investments in R&D, far below the sector’s average at an international level [1,2]. The 
following points present some comments regarding researched variables. 
5.2. Hypotheses Confirmation 
5.2.1. International Strategic Orientation 
Our findings suggest that the PPI defines its internationalization strategies focusing 
on target markets (mean = 1.8; median = 2.0). It was also confirmed that companies with 
ISO in foreign markets achieve higher financial results (H1a, U = 0.500, p = 0.042). The 
validation of H1a is in line with previous research [41,42]. H1b was not validated since no 
differences were evident regarding revenue generated from international activities (see 
Appendix D). 
5.2.2. Competitive Advantages 
It remains unclear whether CA provides a lever for internationalization (mean = 4.40; 
median = 4.00, at the center of the scale). When observed individually, each dimension 
appears to show greater emphasis on SCA (mean = 4.50; median = 4.50), particularly when 
it comes to items related to customer satisfaction and technical/regulatory support 
provided to customers. However, there is no highlight in the PCA (mean = 3.90; median = 
4.00). Despite hypothesis H2a not being confirmed, from our investigation, it is visible that 
the perception of CA is generally associated with higher development levels, thus 
confirming hypothesis H2b and H2c (rs = 0.693; p < 0.05; U = 1.000; p = 0.047 respectively), 
(see Appendix D). CA perception is positively associated with international revenue, as 
observed in the PCA. Internationalization strategies focused on external markets are 
associated with higher levels of CA, specifically PCA and CCA. 
5.2.3. Internationalization Barriers 
Our findings revealed a slight trend towards EIB (mean = 4.80; median = 5.00 vs. 
mean = 4.10; median = 4.00 on IIB) as the biggest obstacle to internationalization. Higher 
perceived levels of IB are negatively associated with companies with higher international 
revenue and CA levels. However, no evidence pointing to differences between IB 
perceptions in relation to ISO was found (see Appendix D, the validation of H3a, H3b and 
the rejection of H3c). Anil et al. [51] identified a surprising positive impact of EIB on 
internationalization performance (but not with IIB). Our results can be considered more 
consensual and in line with Barbosa et al.’s conclusions [19], when they observed that low 
institutional support had a negative influence on export performance. The most evident 
IB was the reduced support for internationalization ventures received from the 
Portuguese Government. Customs tariffs, regulatory requirements and cultural 
differences were also highlighted. These results enabled a better understanding of the 
barriers faced by PPI in their international projects. 
5.2.4. Entry Mode Selection 
In this research, we observed a clear preference for WEM selection, in 80% of the 
sample, with export activities being managed directly from Portugal or through contracts 
with local distributors (mean = 1.20; median = 1.0). None of the respondents chose foreign 
direct investment as the preferred EM. Other studies suggest IEM to be associated with 
higher levels of internationalization [35,53] but not in our research since hypothesis H4, 
was not confirmed (see Appendix D). It seems EM is not a determinant of PPI’s 
internationalization. 
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5.2.5. The Role of R&D 
Our findings revealed strong positive correlations between the investment in R&D 
and the most internationalized companies (rs = 0.716; p < 0.05) as well as with higher 
international turnover (rs = 0.650; p < 0.05), in line with previous research [14,22]. Reis and 
Forte [68] found that several characteristics of companies (ISO and size, for example) are 
important determinants of export intensity. Since this study did confirm hypothesis H5, 
(see Appendix D) our results partially confirm these conclusions, somehow contradicting 
research conclusion’s by Teramae et al. [54]. 
6. Discussion 
The Portuguese pharmaceutical export sector is composed of companies with a 
significant annual turnover, number of employees and international experience. The 
companies’ dimension is significantly larger than the local sector’s average. International 
experience is well consolidated, having exporting activity for over 15 years and being 
present in more than 50 countries. Their global results are considerably dependent on 
international business. In a recent study regarding the Portuguese industrial sector, Reis 
and Forte [68] established that the size of companies, measured by the number of 
employees, is a determinant of export intensity in industrial companies. In our study, a 
strong correlation between the number of employees and total turnover was also observed 
(rs = 0.701; p = 0.05). Exporting PPI seems to follow an internationalization model focused 
on developing the company’s resources and CA which, in turn, have a positive impact on 
the degree of internationalization. These characteristics are similar to those found in 
Uppsala’s internationalization model [25]. However, it is not possible to assume that the 
PPI’s internationalization model follows an incremental pattern. We found that ISO is 
predominantly focused on foreign markets. We have also shown that these companies 
have significantly larger perception of CA and higher revenues, thus confirming what was 
stated in the literature review [40,48]. On the other hand, we observed that ISO focused 
on the Portuguese market acts as a barrier to international development, with a negative 
impact in internationalization intensity and outcomes. 
Our study demonstrated that higher perceptions of CA correspond to lower 
perceptions of IB. It also revealed an interesting positive correlation between PCA 
development, larger international revenue, and R&D investment (rs = 0.693; p = 0.05 and 
rs = 0.846; p = 0.01 respectively). However, CA was generally disregarded by the 
respondents, especially concerning attributes related to innovation and exclusivity, 
indicating a lack of competitiveness in this sector. Several authors [6,7,14,48] found a 
strong association between CA related to innovation, R&D, the development of 
innovative products and higher levels of internationalization and performance. Lower 
perception of PCA reveals a weakness as it represents a limitation to the sustainable 
development of internationalization. This is supported by the poor results in innovation 
indexes, given that only 20% of surveyed companies have innovative products as their 
main object of internationalization. 
It was also possible to understand that companies significantly recognized the impact 
of IB, whether internal or external. Most notably, the limited support from Portuguese 
Institutions and the difficulties in obtaining reliable information from target markets. 
These findings suggest that Government institutions may play an important role as a lever 
for internationalization by providing institutional support to the sector. 
Regarding EM selection, the PPI relies predominantly on EM’s that do not require 
investment. None of the respondents chose foreign direct investment as the main EM, 
considered the highest degree of international development [50,53]. This may be related 
to the fact that this sector’s international development is still at an early stage or, perhaps, 
the biggest limitation is the relative lack of resources and competitiveness on a global 
scale. 
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Our study confirmed a strong positive correlation between R&D investment and 
international revenue, in line with previous research [14,22], despite contradicting the 
unexpected findings from Teramae et al. [54], perhaps due to differences in the sample’s 
characteristics and research design. 
No associations were found between international experience and other studied 
variables. As such, we are led to conclude that, international experience does not have an 
impact on internationalization in PPI, in contrast to many citations found in the literature 
[44,68]. Buckley and Chapman [11] postulated that internationalization attitude can be 
conditioned by the mid-level managers’ view, with direct implications for overall results. 
Perhaps, an analogous conclusion can be drawn from this study, regarding the exporting 
PPI. Another possible argument can be that exported products are characterized by their 
low innovation levels and, consequentially, shorter margins, but this would have to be 
confirmed in future research, as we do not have enough evidence to support this claim. 
Figure 2 represents the relations between determinants confirmed throughout this 
study. The nature of this analysis and the tests that were performed do not permit the 
identification of eventual dependencies or mediator variables [58]. Still, it is possible to 
understand existing interdependencies between these factors and how they relate to the 
internationalization process and sustainability within the PPI. CA is associated with ISO 
and lower perception of IB. These determinants, as well as R&D, are associated with 
higher internationalization turnovers. On the other hand, EM does not appear to be a 
determinant, hence why it was excluded from the final model. 
 
Figure 2. The working model. Solid Lines—confirmed paths. Dashed lines—partially confirmed 
paths. CA—Competitive Advantages. IB—Internationalization Barriers. ISO—International 
Strategic Orientation. IT—International Turnover. R&D—Research and Development. 
7. Conclusions, Limitations and Future Directions 
The Portuguese exporting pharmaceutical sector accounts for about 2% of total 
Portuguese exports [28] and is considerably more export intensive than the country’s 
overall industrial sector [30] with volumes potentially doubling in the next three to five 
years [69]. This sector assumes an evident strategic relevance in the Portuguese economic 
context. The increase in international activity also stems from the loss of profitability in 
the domestic market, which is still the main source of income for most companies in this 
sector. Exporting PPI companies have a reasonable international experience and tend to 
build their strategies with focus on foreign markets. However, per se, this is not enough 
to guarantee better results since international experience seems to have a limited impact 
on global outcomes. One possible explanation is, perhaps, the fact that 80% of sampled 
companies export commodity products, with no innovative or differentiating 
characteristics. This fact may be connected to previous opportunities in the local market. 
However, this does not seem to grant the necessary edge for competing locally or in a 
globalized market. It is clear that this is not the way for achieving sustainable 
development, internally or abroad. These conclusions suggest that the focus should be 
placed on investing in innovative and differentiating activities, enabling the creation of 
more sustainable, long-term internationalization strategies. It is also very clear the existing 
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gap in institutional support to internationalization. Institutions that oversee this sector 
should increase their knowledge regarding the barriers that affect these companies and 
focus their cooperation and assistance efforts on the international expansion of PPI. 
This research’s small sample conditioned the selection of some statistical tests, 
limiting our options to those presented throughout this work [58]. As a suggestion, future 
studies may focus on the development of a conceptual internationalization model, specific 
to the pharmaceutical sector, grounded on the theoretical foundations previously 
presented. 
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Appendix A 
Table A1. Studies on the Internationalization of Pharmaceutical Companies. 












Uppsala 1 EM, IB 
Buckley and 
Chapman 








Conceptual Entry Mode    EM, IB, ISO 
Chittoor and 
Sougata 




Cluster Analysis 40 CA 
Kuntluru et al. 




Life Cicle 103 EM 
Wrona and 
Trapczynski  




OLI 5 CA, EM, IB 
Chitour 
 (2013) [16] 
Conceptual Entry Mode    EM, IB 















Barbosa et al. 







Diaz et al. 
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Rentala et al. 
(2017) [22] 
Empirical Export performance  23 CA 





 30 ISO 
ISO—Internationalization Strategic Orientation; CA—Competitive Advantages; EM—Entry Mode; IB—
Internationalization Barriers. 
Appendix B 
Table A2. Variables, Dimensions and Scale Type. 





Do managers have an effective “international 
mindset” or do they replicate the “local strategy” 
on foreign markets.  




Entry Mode (EM) [61]  1 
Strategies for penetrating foreign markets. 
1: no direct financial investment (export and 
licensing); 2: direct financial investment (Joint 





Cost (CCA) 2 Capture the different competitive advantages and 
their relevance for international activity. 
1: Fully disagree;…; 4: Neither disagree or agree;...; 
7: Fully Agree * 
Ordinal, seven-
point Likert 
Service (SCA) 5 
Product (PCA) 3 
Internationalization 
Barriers (IB) [51] 
Internal (IIB) 6 Captures the main barriers for internationalization 
and whether these are internal or external to the 
company. 
1: Fully disagree;…; 4: Neither disagree or agree;...; 
7: Fully Agree * 
Ordinal, seven-
point Likert External (EIB) 6 
Years of International 
Activity [46,48] 
  1 
1: <5 years; 2: 5–10 years; 3: 11–15 years; 4: 16–20 
years; 5: 21–25 years; 6: 26–30 years; 7: >30 years 
Ordinal, seven 
point 
Countries with Intern. 
Activity [46,48] 
  1 
1: No int. activity; 2: <10 countries; 3: 10–20 
countries; 4: 21–30 countries; 5: 31–40 countries; 6: 
41–50 countries; 7: >50 countries 
Ordinal, seven 
point 
Yearly Turnover [61]   1 
1: <25 M€; 2: 26–50 M€; 3: 51–75 M€; 4: 76–100 M€; 
5: 101–150 M€; 6: 151–200 M€; 7: >200 M€ 
Ordinal, seven 
point 
% International business 
turnover [46,48] 
  1 
1: <15%; 2: 15–30%; 3: 31–45%; 4: 46–60%; 5: 61–
75%; 6: 76–90%; 7: >90% 
Ordinal, seven 
point 
Total number of 
Employees [61] 
  1 
1: <50; 2: 51–100; 3: 101–200; 4: 201–300; 5: 301–400; 
6: 401–500; 7: >500 
Ordinal, seven 
point 
% International business 
employees [46,48] 
  1 
1: <15%; 2: 15–30%; 3: 31–45%; 4: 46–60%; 5: 61–
75%; 6: 76–90%; 7: >90% 
Ordinal, seven 
point 
R&D Investment [14]   1 
% Total turnover attributed to R&D investment. 
1: <6%; 2: 6–8%; 3: 9–11%; 4: 12–14%; 5: 15–17%; 6: 





  1 1: innovative products; 2: commodities/others 
Nominal, two 
point 
* see Appendix C for detailed questions.  
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Appendix C. Variable’s Questionnaire 
ISO Question: Which countries influence the most and/or condition the definition of 
your company’s internationalization strategy? 1—The Portuguese market, our main 
market; 2—The market where we intend to operate. 
EM Question: Entry mode most frequently used when exploring new markets. 1: no 
direct financial investment (export and licensing); 2: direct financial investment (joint 
ventures, direct investment). 
CA Questions: (1–3: CCA dimensions; 4–7: SCA dimensions; 8–10: PCA dimensions). 
Regarding the portfolio of products sold internationally, indicate the degree to which you 
agree or disagree with each of the following sentences: 1—Our manufacturing costs are 
very competitive, generally lower than our competitors. 2—The sales prices we offer our 
international customers are very competitive, generally lower than those offered by our 
competitors. 3—Our delivery times to customers, from ordering to actual shipment of the 
product, are generally lower and better than those practiced by our competitors. 4—The 
technical and regulatory support we provide to international customers is generally 
superior to that of our competitors. 5—In destination markets, users (patients/consumers) 
highly value our products. 6—Customer accessibility to our products / portfolio is 
superior to that of our competitors. 7—Our customers are very satisfied with the overall 
quality of the service we provide. 8—The scale of our product offering in international 
markets is generally superior to that of our competitors. 9—The quality of our products is 
very high, on average higher than that offered by our competitors. 10—The portfolio of 
products sold in international market is predominantly innovative and exclusive, which 
is a great advantage over our competitors. 
IB Questions: (1–6: IIB dimension; 7–12: EIB dimension). Do you consider that the 
following situations condition or constitute barriers to international activity? 1—We 
struggle to receive/obtain reliable information from international markets. 2—We have 
problems with after—sales support and sales follow—up in international markets. 3—My 
company still has a reduced internationalization culture. 4—International business has a 
very high level of risk. 5—My company has difficulty managing logistics in the 
destination markets. 6—There are many communication problems with branches. 7—
Cultural differences in foreign markets are difficult to manage and overcome. 8—We 
struggle to understand/manage the institutional environment (legal, fiscal) in foreign 
markets. 9—The Portuguese State offers limited support for internationalization 
initiatives. 10—Managing regulatory requirements in target markets is difficult. 11—The 
existence of product/manufacturing patents in force in the target markets prevents us 
from marketing our products. 12—Customs tariffs imposed by some countries take away 
our competitiveness. 
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Appendix D 
Table A3. Hypotheses Validation. 
Hypothesis Test Result 
Hypothesis 
Validation 
H1a. Different ISOs have different levels of turnover Mann–Whitney 
U = 0.500 
p = 0.042 
Yes 
H1b. Different ISOs have different levels of international business’ 
turnover 
Mann–Whitney 
U = 1.500 
p = 0.086 
No 
H2a. Companies with more CA are associated with a bigger turnover Spearman’s Correlation 
rs = 0.313 
p > 0.05 
No 
H2b. Companies with more CA are associated with bigger 
international business’ turnover 
Spearman’s Correlation 
rs = 0.693 
p < 0.05 
Yes 
H2c. Companies with more CA are associated with an ISO focused on 
foreign markets 
Mann–Whitney 
U = 1.000 
p = 0.047 
Yes 
H3a. Companies with more IB are expected to have less international 
business’ turnover 
Spearman’s Correlation 
rs = −0.717 
p < 0.05 
Yes 
H3b. Companies with more IB are expected to have less CA Spearman’s Correlation 
rs = −0.785 
p < 0.01 
Yes 
H3c. Companies with less IB are expected to have ISO’s focused on 
foreign markets 
Mann–Whitney 
U = 4.000 
p = 0.273 
No 
H4. IEM corresponds to ISO’s focused on foreign markets Mann–Whitney 
U = 6.000 
p = 0.453 
No 
H5. Large R&D investment is associated with bigger international 
business’ turnover 
Spearman’s Correlation 
rs = 0.650 
p < 0.05 
Yes 
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